Oric Pharmaceuticals (ORIC) News
NASDAQ: ORICHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.36-0.34 (-4.42%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ORIC news summary
We found 7 recent headlines mentioning Oric Pharmaceuticals (ORIC): 2 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, ORIC is down 4.42% at $7.36. The most recent story, "ORIC Pharmaceuticals Reports Third Quarter 2026 Financial Results and Program Updates", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Oric Pharmaceuticals headlines
- ORIC Pharmaceuticals Reports Third Quarter 2026 Financial Results and Program UpdatesORIC Pharmaceuticals, Inc. reported its financial results for the quarter ended September 30, 2026, and provided updates on its clinical programs. Cash, cash equivalents and investments totaled…Nasdaq
- ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program UpdatesInitiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with BayerGlobeNewswire
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…GlobeNewswire
- ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing…GlobeNewswire
- ORIC Pharmaceuticals, Inc. Announces Phase 1b Enozertinib Data and Plans for Phase 3 Redwood-1 Trial in 1H 2027ORIC Pharmaceuticals, Inc. presented an enozertinib (ORIC-114) program update on October 23, 2026 at ESMO Congress 2026. The update covered data from the Phase 1b trial in patients with locally…NasdaqORIC, WSO.B
- ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED…GlobeNewswire
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialIn a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…GlobeNewswire